Roche: Tecentrip authorised by Brussels in NSCLC.
(CercleFinance.com) - Roche has announced that the European Commission has granted marketing authorisation to Tecentriq (atezolizumab) as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
In particular, this approval is based on the results of a large randomised Phase III study which showed that Tecentriq prolongs patients' lives by 4.2 months compared to those treated with docetaxel chemotherapy.
Tecentriq is also a new treatment option for people with metastatic urothelial carcinoma who have been previously treated with platinum-based chemotherapy and those who cannot receive cisplatin chemotherapy.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
In particular, this approval is based on the results of a large randomised Phase III study which showed that Tecentriq prolongs patients' lives by 4.2 months compared to those treated with docetaxel chemotherapy.
Tecentriq is also a new treatment option for people with metastatic urothelial carcinoma who have been previously treated with platinum-based chemotherapy and those who cannot receive cisplatin chemotherapy.
Copyright (c) 2017 CercleFinance.com. All rights reserved.